Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Fineline Cube Mar 10, 2026
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube Mar 10, 2026
Company Deals

Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out

Fineline Cube Mar 11, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Fineline Cube Mar 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...

Company

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban

Fineline Cube Mar 11, 2025

US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...

Company Drug

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment

Fineline Cube Mar 11, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...

Company Digital

Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment

Fineline Cube Mar 11, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...

Company Deals

IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture

Fineline Cube Mar 11, 2025

China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a...

Company Drug

Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy

Fineline Cube Mar 11, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...

Company Deals

Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation

Fineline Cube Mar 11, 2025

China-based gene sequencer specialist Shenzhen GeneMind Biosciences Co., Ltd. has formed a partnership with compatriot...

Company Deals

Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development

Fineline Cube Mar 11, 2025

Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke

Fineline Cube Mar 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the...

Company Drug

InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting

Fineline Cube Mar 10, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...

Company

Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery

Fineline Cube Mar 10, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of...

Company Deals

Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D

Fineline Cube Mar 10, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9...

Company Drug

LiteDD’s LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors

Fineline Cube Mar 10, 2025

The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors

Fineline Cube Mar 10, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...

Company Medical Device

Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit

Fineline Cube Mar 10, 2025

China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...

Company Drug

InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment

Fineline Cube Mar 10, 2025

China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma

Fineline Cube Mar 10, 2025

US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...

Company Deals

Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development

Fineline Cube Mar 10, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...

Company Deals Medical Device

Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion

Fineline Cube Mar 10, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million...

Posts pagination

1 … 165 166 167 … 632

Recent updates

  • SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.